 SAN DIEGO, Jan. 10, 2023 PRNewswire Bio4t2 dosed the first patient with T cells bearing a chimeric antigen receptor CAR that targets overexpression of BT-001 antigen present on various types of solid tumors. The CAR-T B4t2-001 was developed from Bio4t2s PrismCoreTM platform. This clinical trial is at the cutting edge of CAR-T biology and provides ...... 